Global Polymyxins Market Size By Type (Injection Polymyxins, External Polymyxins), By Application (Intestinal Disease, Infection), By Region, And Segment Forecasts, 2023 to 2032

lobal Polymyxins Market Report Description

The Global Polymyxins Market was valued at USD 1.9 billion in 2023 and is projected to surpass USD 3.6 billion by 2031, registering a CAGR of 8.2% during the forecast period of 2023–2031.

Polymyxins, including polymyxin B and polymyxin E (colistin), are last-resort antibiotics used to treat multidrug-resistant (MDR) Gram-negative bacterial infections. The market growth is driven by the increasing prevalence of antibiotic-resistant infections, the rising incidence of hospital-acquired infections (HAIs), and the growing use of polymyxins in critical care settings. Additionally, the rising pipeline of next-generation polymyxin derivatives and regulatory approvals for colistin in human and veterinary medicine are fostering market expansion.

Drivers

1. Rising Antibiotic Resistance

The surge in multidrug-resistant Gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, has increased the reliance on polymyxins as a last-line therapy. This trend is particularly significant in intensive care units where MDR infections are prevalent.

2. Increasing Hospital-Acquired Infections (HAIs)

The global rise in HAIs caused by carbapenem-resistant Enterobacteriaceae (CRE) has created a higher demand for polymyxins. With limited alternative treatments, hospitals are increasingly incorporating polymyxin-based therapies.

3. Expansion of Critical Care and ICU Infrastructure

The growing number of critical care units, especially in emerging economies, is boosting the need for polymyxins, which are commonly used in ICU settings to manage life-threatening infections.

Restraints

1. Nephrotoxicity and Neurotoxicity Concerns

The known toxicity profile of polymyxins, including kidney and neurological damage, limits their prolonged use and necessitates strict dosing guidelines, potentially restricting market uptake.

2. Emergence of Polymyxin Resistance

Despite being a last-resort therapy, resistance to polymyxins is emerging globally, which could reduce their long-term efficacy and impact market demand.

Opportunities

1. Development of Safer Polymyxin Derivatives

Pharmaceutical companies are focusing on developing novel polymyxin analogs with reduced toxicity and improved therapeutic profiles, creating opportunities for new product launches.

2. Increasing Demand in Emerging Markets

Rapid urbanization, insufficient infection control measures, and a higher burden of MDR infections in Asia-Pacific and Latin America are expected to drive market growth in these regions.

3. Veterinary Applications and Regulatory Approvals

The use of polymyxins in veterinary medicine for livestock health management and the growing approval pipeline for animal use further enhance the market potential.

Market by System Type Insights

Based on product type, polymyxin B dominated the market in 2023, driven by its widespread use in treating bloodstream infections and pneumonia caused by MDR pathogens. However, colistin (polymyxin E) is anticipated to witness faster growth due to its cost-effectiveness and high demand in both human and veterinary medicine.

Market by End-use Insights

In terms of end use, the hospital segment accounted for the largest revenue share in 2023, as polymyxins are primarily used in inpatient settings for severe infections. The veterinary segment is expected to grow at a notable rate during the forecast period, driven by the rising use of polymyxins in livestock and poultry health management.

Market by Regional Insights

Asia-Pacific dominated the polymyxins market in 2023, with countries like China and India being major consumers due to a high prevalence of MDR infections and widespread use in veterinary applications.

North America is expected to witness significant growth, fueled by rising awareness of antimicrobial resistance and increased hospital expenditure on last-line antibiotics.

Europe maintains a steady market share owing to stringent infection control policies and advanced healthcare infrastructure.

Competitive Scenario

Key players in the Global Polymyxins Market include Xellia Pharmaceuticals, Pfizer Inc., Cipla Ltd., Valeant Pharmaceuticals, Sandoz International GmbH, Hikma Pharmaceuticals PLC, and Apotex Inc. These companies are focusing on novel polymyxin derivatives, strategic partnerships, and expanding manufacturing capacities to meet the rising global demand.

In 2024, Xellia Pharmaceuticals received FDA approval for a new formulation of polymyxin B with improved safety.

In 2023, Cipla expanded its colistin production facilities in India to meet growing domestic and export demand.

In 2023, Hikma Pharmaceuticals launched a generic polymyxin B sulfate injection in the US market.

Scope of Work – Global Polymyxins Market

Key Market Developments

January 2024 – Xellia Pharmaceuticals received EMA approval for a next-generation polymyxin B analog with reduced nephrotoxicity.

September 2023 – Cipla introduced an affordable generic colistin formulation for emerging markets.

July 2023 – Hikma Pharmaceuticals signed a strategic partnership to distribute polymyxin B across the Middle East and Africa.

FAQs

1. What is the current market size of the Global Polymyxins Market?

The market size was valued at USD 1.9 billion in 2023.

2. What is the major growth driver of the Global Polymyxins Market?

The primary growth driver is the increasing prevalence of multidrug-resistant bacterial infections and rising hospital-acquired infections.

3. Which is the largest region during the forecast period in the Global Polymyxins Market?

Asia-Pacific is the largest and fastest-growing region due to high MDR infection rates and veterinary usage.

4. Which segment accounted for the largest market share in the Global Polymyxins Market?

The hospital segment dominated the market in 2023 due to widespread use in critical care settings.

5. Who are the key market players in the Global Polymyxins Market?

Key players include Xellia Pharmaceuticals, Pfizer, Cipla, Sandoz, and Hikma Pharmaceuticals.

Would you like me to generate similar reports for multiple antibiotic markets (e.g., carbapenems, cephalo